🇺🇸 FDA
Company

VACCINEX,

VACCINEX, INC.

VCNX pharma USA

Quick answer

VACCINEX, is a pharma company (VCNX) headquartered in ROCHESTER, NY, USA with 11 tracked pipeline programs.

Pipeline (11)

project

Avelumab and Pepinemab

Metastatic Pancreatic Adenocarcinoma

Phase 2 · small_molecule · active

1 trials project

VX15/2503

Huntington's Disease

Phase 2 · small_molecule · completed

1 trials project

VX15/2503 + avelumab

Carcinoma, Non-Small-Cell Lung

Phase 2 · small_molecule · completed

1 trials project

pepinemab + pembrolizumab

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Phase 2 · small_molecule · completed

1 trials project

Anti-SEMA4D Monoclonal Antibody VX15/2503

Colon Carcinoma Metastatic in the Liver

Phase 1 · mab · completed

1 trials project

Anti-SEMA4D Monoclonal Antibody VX15/2503

Metastatic Melanoma

Phase 1 · mab · terminated

1 trials project

Dendritic Cell (DC1) Vaccine

HER2-positive Breast Cancer

Phase 1 · mab · active

1 trials project

Ipilimumab

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8

Phase 1 · mab · active

1 trials project

VX15/2503

Multiple Sclerosis

Phase 1 · small_molecule · completed

1 trials project

VX15/2503

Solid Tumors

Phase 1 · small_molecule · completed

1 trials project

VX15/2503

Squamous Cell Carcinoma of the Head and Neck

Phase 1 · mab · active

1 trials

Patents (8)

patent

US 12201719

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12070500

Use of semaphorin-4D antibodies in combination with an immune modulating therapy

Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12006365

Human anti-semaphorin 4D antibody

Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12006364

Anti-CD100 antibodies and methods for using the same

Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11981730

Anti-CXCL13 antibodies and methods of using the same

Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11859000

Anti-CCR8 antibodies and uses thereof

Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11660330

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11597765

Use of semaphorin-4D binding molecules for the treatment of Rett syndrome

Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)